Currently, there are 79.22M common shares owned by the public and among those 65.32M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -57.28% and -86.63% over the past three months. TNYA shares are trading -69.23% year to date (YTD), with the 12-month market performance down to -92.61% lower. It has a 12-month low price of $0.86 and touched a high of $7.01 over the same period. TNYA has an average intraday trading volume of 3.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -55.86%, -63.96%, and -81.95% respectively.
Institutional ownership of Tenaya Therapeutics Inc (NASDAQ: TNYA) shares accounts for 41.54% of the company’s 79.22M shares outstanding.
It has a market capitalization of $34.86M and a beta (3y monthly) value of 2.83. The earnings-per-share (ttm) stands at -$1.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.71% over the week and 13.12% over the month.
Analysts forecast that Tenaya Therapeutics Inc (TNYA) will achieve an EPS of -0.31 for the current quarter, -0.33 for the next quarter and -1.17 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.35 while analysts give the company a high EPS estimate of -0.35. Comparatively, EPS for the current quarter was -0.4 a year ago. Earnings per share for the fiscal year are expected to increase by 19.60%, and 13.46% over the next financial year. EPS should grow at an annualized rate of 11.39% over the next five years, compared to -27.43% over the past 5-year period.
Leerink Partners coverage for the Tenaya Therapeutics Inc (TNYA) stock in a research note released on November 30, 2023 offered a Outperform rating with a price target of $7.
